Genprex Partners With Roche to Refine Lung Cancer Patient Selection

The partnership focuses on leveraging Roche’s expertise in assay development, specifically utilizing a TROP2 antibody that has already secured FDA Breakthrough Device Designation. By aligning its research with Roche’s AI-driven diagnostic framework, Genprex intends to transition from general clinical screening to a more precise, biomarker-informed approach. Previous internal research from the Austin-based firm indicated that patients with high TROP2 expression and low PTEN H-scores exhibited longer progression-free survival, providing the impetus for this validation effort.

Ryan Confer, President and CEO of Genprex, noted that using the same validated antibody as Roche is expected to streamline the identification of suitable candidates for their oncology pipeline. The company plans to wrap up the validation studies by the end of 2026, with the goal of integrating these findings directly into the clinical protocols for REQORSA, their lead gene therapy candidate. This alignment represents a shift toward more tailored oncology interventions, moving away from broader patient cohorts toward individuals identified through specific molecular markers.